Ciprofibrate

Specifications

52214-84-3CAS Number

257-744-6EC Number

2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acidIUPAC Name

C13H14Cl2O3Chemical Formula

289.15 g/molMolecular Weight

Ciprofibrate; 52214-84-3; 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; Ciprofibratum; Ciprofibrato; Modalim; Win-35833; WIN 35833; Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-; DTXSID8020331; NSC-759617; F8252JGO9S; 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid; Propanoic acid, 2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methyl-; DTXCID20331; CHEBI:50867; Hyperlipen; 2-[p-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropionic acid; RefChem:577246; C10AB08; 257-744-6; Lipanor; MFCD00467135; 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid; NCGC00164447-01; Ciprol; 2-[p-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid; 2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid; Ciprofibratum [INN-Latin]; Ciprofibrato [INN-Spanish]; Hiperlipen; SMR000857190; CCRIS 173; BRN 1984981; SR-01000075734; EINECS 257-744-6; Ciprofibrate (USAN/INN); UNII-F8252JGO9S; Ciprofibrate [USAN:INN:BAN]; Ciprol;; Ciprofibrate CRS; Ciprofibrate; 2-[4-[(1RS)-2,2-Dichlorocyclopropyl]phenoxy]-2-methylpropanoic acid; CAS-52214-84-3; Ciprofibrate (Standard); Prestwick0_001076; Prestwick1_001076; Prestwick2_001076; Prestwick3_001076; CIPROFIBRATE [MI]; CIPROFIBRATE [INN]; C 0330; CIPROFIBRATE [USAN]; Lopac0_000168; SCHEMBL26870; BSPBio_001092; CIPROFIBRATE [MART.]; MLS002154143; MLS006011758; CIPROFIBRATE [WHO-DD]; SPBio_002996; BPBio1_001202; CHEMBL557555; GTPL3438; orb1224812; orb1309185; Ciprofibrate - Bio-X trade mark; HY-B0664R; CIPROFIBRATE [EP IMPURITY]; GLXC-05971; HMS1571G14; HMS2098G14; HMS2235J14; HMS3260B17; HMS3369B22; HMS3656P09; HMS3715G14; HMS5081J13; Pharmakon1600-01502008; CIPROFIBRATE [EP MONOGRAPH]; 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-propanoic acid; 2-[4-(2,2-Dichlorocyclopropyl)phenoxy]-2-methylpropionic Acid; HY-B0664; MSK11056; VHD01505; Tox21_112121; Tox21_201359; Tox21_302840; Tox21_500168; BBL010821; BDBM50371235; EBC-26468; NSC759617; s2665; STK624758; Ciprofibrate For System Suitability A; AKOS005557843; Tox21_112121_1; AC-1018; CCG-204263; DB09064; FD11320; KS-1201; LP00168; NSC 759617; SDCCGSBI-0050156.P002; NCGC00015202-02; NCGC00015202-03; NCGC00015202-04; NCGC00015202-05; NCGC00015202-06; NCGC00015202-08; NCGC00015202-18; NCGC00015202-20; NCGC00015202-21; NCGC00093652-01; NCGC00093652-02; NCGC00256361-01; NCGC00258911-01; NCGC00260853-01; BD164311; SY052727; AB00514032; C2667; EU-0100168; NS00032454; SW197242-4; D03521; O10468; AB00514032_06; EN300-18557337; F212903; Q3496452; SR-01000075734-1; SR-01000075734-4; SR-01000075734-7; BRD-A49358627-001-03-9; BRD-A49358627-001-10-4; BRD-A49358627-001-13-8; BRD-A49358627-001-14-6; Ciprofibrate, European Pharmacopoeia (EP) Reference Standard; Ciprofibrate for system suitability, European Pharmacopoeia (EP) Reference StandardSynonyms